U.S. Interactive Media and Services Stock News

NYSE:TFIN
NYSE:TFINBanks

Does Triumph Financial’s (TFIN) Steady Preferred Dividend Reveal Its True Capital Allocation Priorities?

In late February 2026, Triumph Financial, Inc.’s board declared a quarterly cash dividend of US$17.81 per share on its 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock, with holders of NYSE-listed depositary shares receiving US$0.44525 per share payable on March 30, 2026 to investors of record on March 15, 2026. This routine preferred dividend, alongside fresh inflation data that may influence Federal Reserve policy, highlights the contrast between Triumph’s capital return...
NYSE:HE
NYSE:HEElectric Utilities

Hawaiian Electric Wildfire Settlements And New Funding Reframe Risk For Investors

Hawaiian Electric Industries (NYSE: HE) is advancing the resolution of Maui wildfire tort claims, supported by recent favorable court decisions. The company reports progress on a broader settlement framework that aims to bring more clarity to wildfire-related liabilities. HE has secured additional financial flexibility through new utility debt issuance and an expanded revolving credit facility. The utility is continuing to work toward its renewable energy targets while addressing...
NasdaqGS:PPC
NasdaqGS:PPCFood

Pilgrim's Pride (PPC) Is Up 5.3% After Q4 Earnings Beat Led By US Prepared Foods Strength

In February 2026, Pilgrim's Pride reported Q4 2025 earnings that exceeded analyst expectations, driven by strong US operations with volume gains in its fresh portfolio and share growth for the Just Bare prepared foods brand, alongside supportive European performance and weaker results in Mexico. The results highlight how Pilgrim's Pride's focus on higher-value prepared foods and branded offerings like Just Bare is increasingly influencing the mix of its global earnings. We’ll now examine how...
NYSE:CALY
NYSE:CALYLeisure

Callaway’s Refocus on Core Golf and Upgraded Earnings Outlook Could Be A Game Changer For CALY

In recent months, Callaway Golf completed the sale of Jack Wolfskin and Topgolf, reorganizing around two core segments: Golf Equipment and Apparel, Gear and Other, with historical financials recast to reflect these divestitures as discontinued operations. This renewed focus on core golf and apparel, combined with a very large increase in full-year earnings estimates versus 90 days ago, highlights a clearer business profile that investors can more easily assess. We’ll now examine how the...
NYSE:JHG
NYSE:JHGCapital Markets

Is It Too Late To Consider Janus Henderson Group (JHG) After Strong Multi Year Returns?

If you are wondering whether Janus Henderson Group's current share price is giving you fair value or not, it helps to step back and look at what the underlying numbers say. The stock last closed at US$52.10, with recent returns of 3.8% over 7 days, 8.2% over 30 days, 9.0% year to date and 27.2% over the past year, plus very large gains over 3 and 5 years. Recent coverage has focused on Janus Henderson Group's position in the asset management space and how its scale and product range fit into...
NYSE:NFG
NYSE:NFGGas Utilities

Does GARP Recognition And Strong Earnings Shift The Bull Case For National Fuel Gas (NFG)?

In recent reports, National Fuel Gas was highlighted as a leading Growth at a Reasonable Price candidate, with strong past-year earnings growth and revenue expansion alongside valuation metrics that sit below industry averages. This combination of earnings quality, financial stability and comparatively modest pricing has drawn fresh investor attention to a company often viewed primarily as a traditional gas utility. Next, we’ll examine how this GARP recognition and its emphasis on robust...
NasdaqGM:CRVS
NasdaqGM:CRVSBiotechs

Does Corvus Pharmaceuticals’ (CRVS) Soquelitinib Focus Clarify Its Core Strategy or Concentration Risk?

Corvus Pharmaceuticals recently presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, highlighting updated clinical and development plans for its lead candidate soquelitinib across multiple indications. The company emphasized strong early atopic dermatitis data for soquelitinib and outlined an international phase II trial and a phase III lymphoma interim analysis, underscoring how this single asset anchors its clinical pipeline. We will now examine how the emerging...
NYSE:ST
NYSE:STElectrical

Is Sensata Technologies (ST) Share Price Attractive After Mixed Multi Year Returns?

If you are wondering whether Sensata Technologies Holding's current share price reflects its true worth, you are not alone. Many investors are asking the same question. The stock last closed at US$37.34, with returns of 0.9% over 7 days, 8.0% over 30 days, 7.0% year to date and 38.8% over 1 year, while the 3 year and 5 year returns sit at 23.7% and 33.1% declines respectively. These mixed returns set the scene for a closer look at what recent developments might mean for the business and its...
NasdaqGS:SBGI
NasdaqGS:SBGIMedia

Assessing Sinclair (SBGI) Valuation After Recent Share Price Momentum

Why Sinclair Is On Investors’ Radar Right Now Sinclair (SBGI) has drawn attention after recent share price moves, with the stock around $16.34 and showing double digit returns over the past month and past three months, prompting fresh interest in its current valuation. See our latest analysis for Sinclair. The recent momentum, with a 7 day share price return of 11.92% and 30 day share price return of 12.61% at a current share price of $16.34, sits alongside a 1 year total shareholder return...
NasdaqGS:ORLY
NasdaqGS:ORLYSpecialty Retail

How Investors May Respond To O’Reilly Automotive (ORLY) Accelerating 2026 Store Openings Amid DIY Headwinds

O’Reilly Automotive has already outlined plans in its 2025 Form 10-K to open 225 to 235 new stores in 2026, while integrating its 2024 acquisition of Groupe Del Vasto and expanding its dual DIY and professional automotive parts offering across North America. Recent commentary highlights that, even as inflation and tariffs pressure the do-it-yourself segment, O’Reilly’s professional business and distribution network are supporting ongoing expansion and attracting renewed attention from...
NYSE:H
NYSE:HHospitality

A Look At Hyatt Hotels (H) Valuation After Recent Share Price Volatility

Hyatt Hotels (H) is back on investors’ radar after recent share price moves, with the stock showing mixed short term performance and a stronger picture over the past year and multi year periods. See our latest analysis for Hyatt Hotels. The latest 5.7% one day share price decline to US$161.50 comes after a period of steadier gains, with a 1 year total shareholder return of 15.8% and 5 year total shareholder return of 86.9%. This suggests longer term momentum remains intact despite short term...
NYSE:ALLE
NYSE:ALLEBuilding

Schlage Aspect Collection Launch Adds New Angle To Allegion Growth Story

Schlage, part of Allegion, has launched the Aspect Collection of interior door hardware, focused on bold design and easier installation. The collection expands Allegion's design centric portfolio and targets homeowners and professionals looking for more modern style options. The announcement highlights Allegion's emphasis on combining aesthetics with everyday usability in its residential product lineup. For investors watching Allegion (NYSE:ALLE), the Aspect Collection lands at a time when...
NYSE:PSN
NYSE:PSNProfessional Services

Bastion’s Parsons Bet Highlights Tension Between Volatile Trading And Long Term Themes

Bastion Asset Management has opened a significant new equity position in Parsons (NYSE:PSN). The holding ranks as a substantial position within Bastion’s portfolio. The move adds a new institutional holder to Parsons, which focuses on government and critical infrastructure projects. Parsons, traded on the NYSE under the ticker PSN, works across defense, intelligence, and critical infrastructure, areas that often rely on long term federal and public sector contracts. For investors watching...
NYSE:CVSA
NYSE:CVSAConsumer Services

Covista Rebrand Pairs New Ticker With Three Year Growth Targets

Covista Inc., formerly Adtalem Global Education Inc., has completed a full corporate rebrand and name change. The company has also updated its ticker symbol to NYSE:CVSA. Alongside the rebrand, Covista introduced a three year growth plan targeting the U.S. healthcare workforce shortage. Covista operates in healthcare education, a segment that sits at the center of ongoing shortages across many clinical roles in the U.S. The company is presenting its new identity and plan as a response to...
NYSE:RBRK
NYSE:RBRKSoftware

Rubrik’s Growth Story Weighs Market Share Potential Against Ongoing Losses

Rubrik (NYSE:RBRK) is drawing fresh attention as recent updates highlight strong revenue gains, high net retention, and solid margins. The company reports operating with a very low share of its target market, which points to meaningful room for further enterprise cybersecurity adoption. Management continues to emphasize Rubrik’s subscription-based model and high switching costs as key supports for its position in data security. At a share price of $51.96, NYSE:RBRK sits against a backdrop...
NYSE:LII
NYSE:LIIBuilding

Does LII’s Earnings Miss and Insider Sale Change The Bull Case For Lennox International?

Lennox International recently reported its fourth-quarter 2025 results, with both earnings per share and revenue coming in below analyst forecasts, while director Shane D. Wall sold 100 shares of common stock on February 25, 2026. This combination of an earnings shortfall and insider selling has sharpened investor focus on how resilient Lennox’s longer-term HVAC growth story may be. We’ll now examine how the weaker-than-expected quarterly earnings could influence Lennox’s previously outlined...
NasdaqCM:SKYT
NasdaqCM:SKYTSemiconductor

SkyWater Technology (SKYT) Is Up 6.1% After Swing To 2025 Profitability And New Sales Leadership - Has The Bull Case Changed?

SkyWater Technology, Inc. reported past fourth-quarter 2025 sales of US$171.04 million versus US$75.49 million a year earlier, with a quarterly net loss of US$7.78 million, while full-year 2025 sales reached US$442.14 million and net income was US$118.92 million, reversing the prior year’s loss. Alongside these results, the company is sharpening its focus on growth and customer acquisition, appointing veteran semiconductor executive Christine Dunbar to lead sales and solutions engineering as...
NYSE:SYY
NYSE:SYYConsumer Retailing

Sysco Expands Local Sourcing And Coffee Partnership As Valuation Draws Interest

Sysco has launched a new pilot program, Home Grown by Sysco, to expand locally sourced food offerings across select regions in North America. The company has also signed a nationwide distribution partnership with Reborn Coffee to support the coffee brand's franchise expansion across the United States. For investors watching NYSE:SYY, these moves come as Sysco trades around $91.16 per share, with returns of 25.5% year to date and 23.8% over the past year. The stock has also returned 29.6%...
NasdaqGS:UPWK
NasdaqGS:UPWKProfessional Services

Is Now The Time To Reassess Upwork (UPWK) After Recent Share Price Slide

If you are wondering whether Upwork's recent share price swings have created an opportunity or a value trap, looking closely at what the market is actually pricing in can help frame your next move. Upwork's shares last closed at US$13.42, with a 7 day return of 7.3%, a 30 day return of a 33.0% decline, a year to date return of a 32.4% decline, a 1 year return of an 8.8% decline, a 3 year return of 12.5% and a 5 year return of a 68.2% decline. Recent attention on Upwork has centered on how...
NasdaqGS:DAWN
NasdaqGS:DAWNBiotechs

Does Day One Biopharmaceuticals (DAWN) Share Price Reflect Its Oncology Pipeline Prospects?

If you are wondering whether Day One Biopharmaceuticals' current share price lines up with its underlying worth, you are not alone. The stock most recently closed at US$10.60, with a 7 day return of 10% decline, a 30 day return of 5% decline, gains of 19.8% year to date and 17% over the past year, while the 3 year return sits at 43.4% decline. Recent news around Day One has largely focused on its development stage oncology pipeline and ongoing progress in clinical programs, which can...
NYSE:AEE
NYSE:AEEIntegrated Utilities

The Bull Case For Ameren (AEE) Could Change Following New Long‑Term Fixed‑Rate Debt Strategy Shift

Ameren Corporation recently completed several fixed‑income transactions, including a US$399.21 million offering of 5% senior notes due 2036, alongside earlier first mortgage bond issuances by Ameren Missouri to refinance short‑term debt and support grid investments. Together, these bond deals reshape Ameren’s funding mix by locking in long‑term, fixed‑rate capital and reducing refinancing uncertainty around its large infrastructure program. Next, we’ll explore how Ameren’s shift toward...
NasdaqGS:DHC
NasdaqGS:DHCHealth Care REITs

A Look At Diversified Healthcare Trust (DHC) Valuation After Earnings Reveal Narrower Net Loss

What the latest earnings tell you about Diversified Healthcare Trust Diversified Healthcare Trust (DHC) has just reported fourth quarter and full year 2025 results, showing lower quarterly sales but a narrower net loss, a combination that naturally puts the stock back on investors’ radar. See our latest analysis for Diversified Healthcare Trust. That earnings update landed after a strong run in the shares, with a 90 day share price return of 39.96% and a year to date share price return of...
NasdaqGM:MNKD
NasdaqGM:MNKDBiotechs

A Look At MannKind (MNKD) Valuation After New United Therapeutics Inhaler Raises Royalty Concerns

MannKind (MNKD) is back in focus after partner United Therapeutics introduced a soft mist inhaler designed to compete with Tyvaso DPI, raising fresh questions around MannKind’s future royalty stream and overall risk profile. See our latest analysis for MannKind. The stock’s 7 day share price return of 40.79% and 30 day share price return of 43.25% follow earnings that paired higher revenue with a quarterly loss, while the United Therapeutics soft mist inhaler news sharply reset sentiment...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Assessing Vera Therapeutics (VERA) Valuation After FDA Priority Review And Phase 3 IgAN Success

Vera Therapeutics (VERA) is back in focus after the FDA granted priority review to its lead drug candidate, atacicept, following positive Phase 3 IgA nephropathy data and company updates on funding and launch readiness. See our latest analysis for Vera Therapeutics. Despite the FDA priority review and Phase 3 success for atacicept, Vera Therapeutics’ recent share price returns have cooled, with a 30 day share price return decline of 5.71% and a year to date share price return decline of...